Skip to main content
NCBI home page
British Heart Journal logoLink to British Heart Journal
. 1994 Mar;71(3):261–267. doi: 10.1136/hrt.71.3.261

Cardiac neuropeptide Y and noradrenaline balance in patients with congestive heart failure.

Q P Feng 1, T Hedner 1, B Andersson 1, J M Lundberg 1, F Waagstein 1
PMCID: PMC483664  PMID: 8142196

Abstract

OBJECTIVE--To measure plasma concentrations of noradrenaline and neuropeptide Y-like immunoreactivity in relation to cardiac function in patients with congestive heart failure. DESIGN--Retrospective analysis of plasma noradrenaline concentrations and neuropeptide Y-like immunoreactivity in the arterial and coronary circulations, in patients with a high or low ejection fraction (31.3% (1.3%) or 17.7% (1.1%) respectively) and in healthy volunteers. SETTING--Cardiology department of a university hospital. PATIENTS--41 patients with congestive heart failure with various aetiologies. Ten healthy volunteers served as a reference group. MAIN OUTCOME MEASURES--Concentrations of noradrenaline measured by high performance liquid chromatography and of neuropeptide Y-like immunoreactivity measured by radioimmunoassay. Cardiac index, pulmonary capillary wedge pressure, pulmonary vascular resistance, and systemic vascular resistance were derived by catheterisation of the right heart. Ejection fraction was measured by radionuclide angiography, cineangiography, or M mode echocardiography. RESULTS--There were pronounced and significant increases in circulating arterial concentrations of neuropeptide Y-like immunoreactivity and noradrenaline in both the high and low ejection fraction groups compared with the healthy subjects. In the patients myocardial release of neuropeptide Y-like immunoreactivity tended to be greater compared with normal subjects, but not significantly so. While normal subjects showed myocardial noradrenaline uptake, patients with congestive heart failure showed significant and progressive myocardial noradrenaline release. Arterial as well as coronary sinus concentrations of neuropeptide Y-like immunoreactivity correlated significantly with plasma noradrenaline concentrations from the respective sites. Plasma noradrenaline concentrations in the artery and coronary sinus were negatively correlated with ejection fraction and cardiac index; no such relations were found for concentrations of neuropeptide Y-like immunoreactivity. CONCLUSIONS--Both circulating concentrations of neuropeptide Y-like immunoreactivity and noradrenaline are significantly increased in moderate to severe forms of congestive heart failure. Plasma concentrations of neuropeptide Y-like immunoreactivity correlated with plasma noradrenaline concentrations, but plasma noradrenaline concentrations alone correlated with ejection fraction and cardiac index. Thus plasma noradrenaline concentration seems to be a more sensitive index of cardiac dysfunction than the concentration of neuropeptide Y-like immunoreactivity in congestive heart failure.

Full text

PDF
261

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aizawa Y., Murata M., Hayashi M., Funazaki T., Ito S., Shibata A. Vasoconstrictor effect of neuropeptide Y (NPY) on canine coronary artery. Jpn Circ J. 1985 Jun;49(6):584–588. doi: 10.1253/jcj.49.584. [DOI] [PubMed] [Google Scholar]
  2. Allen J. M., Bircham P. M., Edwards A. V., Tatemoto K., Bloom S. R. Neuropeptide Y (NPY) reduces myocardial perfusion and inhibits the force of contraction of the isolated perfused rabbit heart. Regul Pept. 1983 Jul;6(3):247–253. doi: 10.1016/0167-0115(83)90143-x. [DOI] [PubMed] [Google Scholar]
  3. Allen J. M., Gjörstrup P., Björkman J. A., Ek L., Abrahamsson T., Bloom S. R. Studies on cardiac distribution and function of neuropeptide Y. Acta Physiol Scand. 1986 Mar;126(3):405–411. doi: 10.1111/j.1748-1716.1986.tb07834.x. [DOI] [PubMed] [Google Scholar]
  4. Anderson F. L., Port J. D., Reid B. B., Larrabee P., Hanson G., Bristow M. R. Myocardial catecholamine and neuropeptide Y depletion in failing ventricles of patients with idiopathic dilated cardiomyopathy. Correlation with beta-adrenergic receptor downregulation. Circulation. 1992 Jan;85(1):46–53. doi: 10.1161/01.cir.85.1.46. [DOI] [PubMed] [Google Scholar]
  5. Caidahl K., Hedner J., Hedner T. Atrial natriuretic peptide and catecholamines in peripheral blood as indicators of cardiac dysfunction in the general population. Clin Sci (Lond) 1988 Jun;74(6):587–594. doi: 10.1042/cs0740587. [DOI] [PubMed] [Google Scholar]
  6. Clarke J. G., Davies G. J., Kerwin R., Hackett D., Larkin S., Dawbarn D., Lee Y., Bloom S. R., Yacoub M., Maseri A. Coronary artery infusion of neuropeptide Y in patients with angina pectoris. Lancet. 1987 May 9;1(8541):1057–1059. doi: 10.1016/s0140-6736(87)90483-1. [DOI] [PubMed] [Google Scholar]
  7. Cleland J. G., Dargie H. J., Hodsman G. P., Ball S. G., Robertson J. I., Morton J. J., East B. W., Robertson I., Murray G. D., Gillen G. Captopril in heart failure. A double blind controlled trial. Br Heart J. 1984 Nov;52(5):530–535. doi: 10.1136/hrt.52.5.530. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Cohn J. N., Levine T. B., Olivari M. T., Garberg V., Lura D., Francis G. S., Simon A. B., Rector T. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1984 Sep 27;311(13):819–823. doi: 10.1056/NEJM198409273111303. [DOI] [PubMed] [Google Scholar]
  9. Dahlöf C., Dahlöf P., Lundberg J. M. Neuropeptide Y (NPY): enhancement of blood pressure increase upon alpha-adrenoceptor activation and direct pressor effects in pithed rats. Eur J Pharmacol. 1985 Feb 26;109(2):289–292. doi: 10.1016/0014-2999(85)90433-9. [DOI] [PubMed] [Google Scholar]
  10. DiCarlo L., Chatterjee K., Parmley W. W., Swedberg K., Atherton B., Curran D., Cucci M. Enalapril: a new angiotensin-converting enzyme inhibitor in chronic heart failure: acute and chronic hemodynamic evaluations. J Am Coll Cardiol. 1983 Nov;2(5):865–871. doi: 10.1016/s0735-1097(83)80233-2. [DOI] [PubMed] [Google Scholar]
  11. Francis G. S., Goldsmith S. R., Levine T. B., Olivari M. T., Cohn J. N. The neurohumoral axis in congestive heart failure. Ann Intern Med. 1984 Sep;101(3):370–377. doi: 10.7326/0003-4819-101-3-370. [DOI] [PubMed] [Google Scholar]
  12. Francis G. S., Rector T. S., Cohn J. N. Sequential neurohumoral measurements in patients with congestive heart failure. Am Heart J. 1988 Dec;116(6 Pt 1):1464–1468. doi: 10.1016/0002-8703(88)90729-6. [DOI] [PubMed] [Google Scholar]
  13. Ganz W., Tamura K., Marcus H. S., Donoso R., Yoshida S., Swan H. J. Measurement of coronary sinus blood flow by continuous thermodilution in man. Circulation. 1971 Aug;44(2):181–195. doi: 10.1161/01.cir.44.2.181. [DOI] [PubMed] [Google Scholar]
  14. Gu J., Polak J. M., Allen J. M., Huang W. M., Sheppard M. N., Tatemoto K., Bloom S. R. High concentrations of a novel peptide, neuropeptide Y, in the innervation of mouse and rat heart. J Histochem Cytochem. 1984 May;32(5):467–472. doi: 10.1177/32.5.6546942. [DOI] [PubMed] [Google Scholar]
  15. Hanko J. H., Törnebrandt K., Hardebo J. E., Kåhrström J., Nobin A., Owman C. Neuropeptide Y induces and modulates vasoconstriction in intracranial and peripheral vessels of animals and man. J Auton Pharmacol. 1986 Jun;6(2):117–124. doi: 10.1111/j.1474-8673.1986.tb00638.x. [DOI] [PubMed] [Google Scholar]
  16. Hasking G. J., Esler M. D., Jennings G. L., Burton D., Johns J. A., Korner P. I. Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity. Circulation. 1986 Apr;73(4):615–621. doi: 10.1161/01.cir.73.4.615. [DOI] [PubMed] [Google Scholar]
  17. Hjemdahl P., Daleskog M., Kahan T. Determination of plasma catecholamines by high performance liquid chromatography with electrochemical detection: comparison with a radioenzymatic method. Life Sci. 1979 Jul 9;25(2):131–138. doi: 10.1016/0024-3205(79)90384-9. [DOI] [PubMed] [Google Scholar]
  18. Hughes J., Roth R. H. Evidence that angiotensin enhances transmitter release during sympathetic nerve stimulation. Br J Pharmacol. 1971 Feb;41(2):239–255. doi: 10.1111/j.1476-5381.1971.tb08025.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Hulting J., Sollevi A., Ullman B., Franco-Cereceda A., Lundberg J. M. Plasma neuropeptide Y on admission to a coronary care unit: raised levels in patients with left heart failure. Cardiovasc Res. 1990 Feb;24(2):102–108. doi: 10.1093/cvr/24.2.102. [DOI] [PubMed] [Google Scholar]
  20. Kaijser L., Pernow J., Berglund B., Lundberg J. M. Neuropeptide Y is released together with noradrenaline from the human heart during exercise and hypoxia. Clin Physiol. 1990 Mar;10(2):179–188. doi: 10.1111/j.1475-097x.1990.tb00252.x. [DOI] [PubMed] [Google Scholar]
  21. Leimbach W. N., Jr, Wallin B. G., Victor R. G., Aylward P. E., Sundlöf G., Mark A. L. Direct evidence from intraneural recordings for increased central sympathetic outflow in patients with heart failure. Circulation. 1986 May;73(5):913–919. doi: 10.1161/01.cir.73.5.913. [DOI] [PubMed] [Google Scholar]
  22. Lundberg J. M., Hua X. Y., Franco-Cereceda A. Effects of neuropeptide Y (NPY) on mechanical activity and neurotransmission in the heart, vas deferens and urinary bladder of the guinea-pig. Acta Physiol Scand. 1984 Aug;121(4):325–332. doi: 10.1111/j.1748-1716.1984.tb07463.x. [DOI] [PubMed] [Google Scholar]
  23. Lundberg J. M., Hökfelt T., Anggård A., Kimmel J., Goldstein M., Markey K. Coexistence of an avian pancreatic polypeptide (APP) immunoreactive substance and catecholamine in some peripheral and central neurons. Acta Physiol Scand. 1980 Sep;110(1):107–109. doi: 10.1111/j.1748-1716.1980.tb06638.x. [DOI] [PubMed] [Google Scholar]
  24. Lundberg J. M., Martinsson A., Hemsén A., Theodorsson-Norheim E., Svedenhag J., Ekblom B., Hjemdahl P. Co-release of neuropeptide Y and catecholamines during physical exercise in man. Biochem Biophys Res Commun. 1985 Nov 27;133(1):30–36. doi: 10.1016/0006-291x(85)91837-6. [DOI] [PubMed] [Google Scholar]
  25. Lundberg J. M., Terenius L., Hökfelt T., Martling C. R., Tatemoto K., Mutt V., Polak J., Bloom S., Goldstein M. Neuropeptide Y (NPY)-like immunoreactivity in peripheral noradrenergic neurons and effects of NPY on sympathetic function. Acta Physiol Scand. 1982 Dec;116(4):477–480. doi: 10.1111/j.1748-1716.1982.tb07171.x. [DOI] [PubMed] [Google Scholar]
  26. Maisel A. S., Scott N. A., Motulsky H. J., Michel M. C., Boublik J. H., Rivier J. E., Ziegler M., Allen R. S., Brown M. R. Elevation of plasma neuropeptide Y levels in congestive heart failure. Am J Med. 1989 Jan;86(1):43–48. doi: 10.1016/0002-9343(89)90228-3. [DOI] [PubMed] [Google Scholar]
  27. Morris M. J., Russell A. E., Kapoor V., Cain M. D., Elliott J. M., West M. J., Wing L. M., Chalmers J. P. Increases in plasma neuropeptide Y concentrations during sympathetic activation in man. J Auton Nerv Syst. 1986 Oct;17(2):143–149. doi: 10.1016/0165-1838(86)90089-5. [DOI] [PubMed] [Google Scholar]
  28. Pernow J., Lundberg J. M., Kaijser L., Hjemdahl P., Theodorsson-Norheim E., Martinsson A., Pernow B. Plasma neuropeptide Y-like immunoreactivity and catecholamines during various degrees of sympathetic activation in man. Clin Physiol. 1986 Dec;6(6):561–578. doi: 10.1111/j.1475-097x.1986.tb00789.x. [DOI] [PubMed] [Google Scholar]
  29. Pernow J., Lundberg J. M., Kaijser L. Vasoconstrictor effects in vivo and plasma disappearance rate of neuropeptide Y in man. Life Sci. 1987 Jan 5;40(1):47–54. doi: 10.1016/0024-3205(87)90251-7. [DOI] [PubMed] [Google Scholar]
  30. Pfeffer M. A., Braunwald E., Moyé L. A., Basta L., Brown E. J., Jr, Cuddy T. E., Davis B. R., Geltman E. M., Goldman S., Flaker G. C. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992 Sep 3;327(10):669–677. doi: 10.1056/NEJM199209033271001. [DOI] [PubMed] [Google Scholar]
  31. Rioux F., Bachelard H., Martel J. C., St-Pierre S. The vasoconstrictor effect of neuropeptide Y and related peptides in the guinea pig isolated heart. Peptides. 1986 Jan-Feb;7(1):27–31. doi: 10.1016/0196-9781(86)90056-2. [DOI] [PubMed] [Google Scholar]
  32. Schuler G., Hambrecht R., Schlierf G., Niebauer J., Hauer K., Neumann J., Hoberg E., Drinkmann A., Bacher F., Grunze M. Regular physical exercise and low-fat diet. Effects on progression of coronary artery disease. Circulation. 1992 Jul;86(1):1–11. doi: 10.1161/01.cir.86.1.1. [DOI] [PubMed] [Google Scholar]
  33. Theodorsson-Norheim E., Hemsén A., Lundberg J. M. Radioimmunoassay for neuropeptide Y (NPY): chromatographic characterization of immunoreactivity in plasma and tissue extracts. Scand J Clin Lab Invest. 1985 Jun;45(4):355–365. doi: 10.3109/00365518509161019. [DOI] [PubMed] [Google Scholar]
  34. Wahlestedt C., Edvinsson L., Ekblad E., Håkanson R. Neuropeptide Y potentiates noradrenaline-evoked vasoconstriction: mode of action. J Pharmacol Exp Ther. 1985 Sep;234(3):735–741. [PubMed] [Google Scholar]
  35. Wahlestedt C., Wohlfart B., Håkanson R. Effects of neuropeptide Y (NPY) on isolated guinea-pig heart. Acta Physiol Scand. 1987 Apr;129(4):459–463. doi: 10.1111/j.1365-201x.1987.tb10618.x. [DOI] [PubMed] [Google Scholar]
  36. Zimmerman B. G. Actions of angiotensin on adrenergic nerve endings. Fed Proc. 1978 Feb;37(2):199–202. [PubMed] [Google Scholar]

Articles from British Heart Journal are provided here courtesy of BMJ Publishing Group

RESOURCES